ABSTRACT
@EN Ipriflavone, a synthetic isoflavone, reduces bone resorption by inhibiting osteoclastic activity. Compared to estrogen replacement therapy, ipriflavone had no risk of breast or endometrial cancer.
We studed 24 cases of postmenopausal women. Nineteen patients on postmenopausal women were treated with 600mg/day of ipriflavone (Teobone) by oral administration in 3 daily doses (treatment group), and five patients with placebo (control group).
we
studed nutritional status, biochemical bone marker, night time 12-hoir urine pyridinoline/creatinine (PYD/Cr), and serum osteocalcin level. @ES Our results were as followed.
@EN 1. Mean age of treated group and control group were 62±6 years, and 58±2 years old, respectively. Total calcium and animal calcium intake were 654±270 vs 599±254 mg/day and 276±199 vs 244±289 mg/day, respectively.
2. Degree of bone pains was divided into no pain (0 point), moderate (2 points), and severe group (3 points). Treatment group improved pain score from 2.05±0.62 to 1.26±0.45 points, but control group had no interval change.
3. Serum level of calcium and inorganic phosphorus had no interval change before and after treatment, but serum level of alkaline phosphatase was significantly increased from 55±17 IU/L to 61±19IU/L in control group. However there was no change
in
treatment group.
4. Night time collected 12-hour urine PYD/Cr ratio was significantly decreased from 53±33 nM/mM to 42±32 nM/mM in treatment group, but there was no significant change in control group. Serum osteocalcin level was not significantly changed in
treatment
group.
In conclusion, ipriflavone had effect no reliving bon pain and inhibiting bone resorption in patients with postmenopaual osteoporosis. (J Kor Soc Endocrinol 8:259~264, 1993)
|